Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma
Authors' conclusion
Cabozantinib is an effective and reasonably well-tolerated treatment option for patients with PDTC. Prospective studies are needed to further investigate the role of cabozantinib in the treatment of PDTC, alone and in combination with other agents, including checkpoint inhibitors.
Study context
- Population
- Patients with poorly differentiated thyroid carcinoma (PDTC) who received cabozantinib in any line of therapy
- Participants
- 7 patients
- Outcome
- Median PFS and OS, estimated by Kaplan-Meier
Methodological detailssingle-institution
- Single-institution
Main finding
As reported in the abstract
Median progression-free survival (PFS) from start of cabozantinib
12.9 months
Median overall survival (OS)
14.21 months
Observational data: associations, not effects.
Further findings
Best response
- Partial response
- 4/7 (57%)
- Stable disease
- 2/7 (29%)
Median time on treatment
- Median time on cabozantinib
- 10.53 months
Alive at last follow-up
- Patients alive
- Two (29%)
Safety
- Low-grade adverse events
- 5/6
Original publication
Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma. Eur Thyroid J. Published 20 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →